Trending

biosimilars Europe

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European

X

AbbVie braces for impact of Humira biosimilars in Europe

https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/

Fourth Humira biosimilar set for EU approval

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s

X

Fourth Humira biosimilar set for EU approval

https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/

EC to update IP rules to benefit generic exports

EC to update IP rules to benefit generic exports

The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.

X

EC to update IP rules to benefit generic exports

https://pharmaphorum.com/news/ec-update-ip-rules-generic-exports/

3 Questions on biosimilars in Europe: Adrian van den Hoven

3 Questions on biosimilars in Europe: Adrian van den Hoven

Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.

X

3 Questions on biosimilars in Europe: Adrian van den Hoven

https://pharmaphorum.com/views-and-analysis/biosimilars-3-questions-adrian-van-den-hoven-medicines-europe/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com